about
Therapeutically targeting SELF-reinforcing leukemic niches in acute myeloid leukemia: A worthy endeavor?Adult onset hemophagocytic lymphohistiocytosis prognosis is affected by underlying disease and coexisting viral infection: analysis of a single institution series of 35 patients.Is Having Clonal Cytogenetic Abnormalities the Same as Having Leukaemia.Prognostic role of baseline 18F-FDG PET/CT parameters in MALT lymphomaShort course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA studyETV6: A Candidate Gene for Predisposition to "Blend Pedigrees"? A Case Report from the NEXT-Famly Clinical TrialThe e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitorsMultidimensional geriatric assessment for elderly hematological patients (≥60 years) submitted to allogeneic stem cell transplantation. A French-Italian 10-year experience on 228 patients
P50
Q38715325-73370638-55F2-493A-89F1-BBB41BCCAACFQ40102961-BC193E42-775C-4240-A87F-34BA36446B1BQ40533740-F707F6E6-AF55-4E2C-A2C6-BD96584AE5F7Q57288768-2D6E02DC-9C8E-4176-887A-081BCD6AA6DDQ89093206-51CEEEA1-F2A5-4B3E-B912-8E7BF918D11AQ90151371-2E501F3E-5094-41CA-A0C6-0B47290B4BE5Q91305076-90813903-7291-4E96-9DA9-C80B099207B1Q94600301-376EF399-A91F-4B72-ADF1-7F85DDE44D05
P50
description
investigador
@es
researcher
@en
name
Mirko Farina
@en
type
label
Mirko Farina
@en
prefLabel
Mirko Farina
@en
P108
P31
P496
0000-0002-2980-9028